Thomas Raymond Slaney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Raymond Slaney has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Robert T. Kennedy
Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, USA
7 shared publications - Li Tao
Analytical Development and Attribute Sciences, Biologics Development, Global Product Development and Supply, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States
5 shared publications - Brandon T. Ruotolo
University of Michigan
4 shared publications Naresh Chennamsetty
Bristol Myers Squibb
4 shared publicationsGuodong Chen
Bristol Myers Squibb
3 shared publicationsLi Tao
Molecular and Analytical Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, New Jersey 08534
3 shared publications
Latest Publications
- 25 August 2026
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 37 (10) , 2525-2533
Ion Mobility-Collision Induced Unfolding Detects Stability Shifts within Hidden Protein Conformer Families
Proteins commonly exist in complex mixtures, adopting a diverse ensemble of structural conformations. While some of these conformations are functionally important, others (e.g., preaggregative states), can adversely affect protein function. In monoclonal antibody (mAb)-based biotherapeutics such structural polydispersity is essential for native function but requires advanced biophysical and analytical techniques to assess and properly engineer optimal therapeutics. Methods such as native mass spectrometry (MS) and ion mobility-mass spectrometry (IM-MS) have become increasingly valuable for studying protein structure. Collision induced unfolding (CIU), an IM-MS assay, is frequently used to examine global higher-order structures of proteins. However, standard CIU assays are fundamentally limited by the IM resolution achieved for the precursor ion population, which may contain multiple conformers with similar collision cross sections. In this report, we use cyclic IM-MS (cIM-MS) to develop and conduct IM-selected CIU assays, which show dramatically enhanced capabilities for analyzing structurally polydisperse samples. To develop the IM-CIU approach, we investigate the model protein bovine serum albumin under both low and neutral pH conditions, demonstrating that IM-CIU can accurately identify domain III as the most perturbed region of the protein under these conditions. Additionally, we apply IM-CIU to analyze interleukin dimers, previously linked in therapeutic fusion protein constructs, and demonstrate that they exist in two distinct solution-based conformations. We conclude by outlining the fundamental principles of the IM-CIU method, highlighting its ability to resolve proteins with near-identical collision cross sections, and discussing its potential impact on the development of future pharmaceutical applications.
- 25 August 2026
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 37 (10) , 2525-2533
Ion Mobility-Collision Induced Unfolding Detects Stability Shifts within Hidden Protein Conformer Families
Proteins commonly exist in complex mixtures, adopting a diverse ensemble of structural conformations. While some of these conformations are functionally important, others (e.g., preaggregative states), can adversely affect protein function. In monoclonal antibody (mAb)-based biotherapeutics such structural polydispersity is essential for native function but requires advanced biophysical and analytical techniques to assess and properly engineer optimal therapeutics. Methods such as native mass spectrometry (MS) and ion mobility-mass spectrometry (IM-MS) have become increasingly valuable for studying protein structure. Collision induced unfolding (CIU), an IM-MS assay, is frequently used to examine global higher-order structures of proteins. However, standard CIU assays are fundamentally limited by the IM resolution achieved for the precursor ion population, which may contain multiple conformers with similar collision cross sections. In this report, we use cyclic IM-MS (cIM-MS) to develop and conduct IM-selected CIU assays, which show dramatically enhanced capabilities for analyzing structurally polydisperse samples. To develop the IM-CIU approach, we investigate the model protein bovine serum albumin under both low and neutral pH conditions, demonstrating that IM-CIU can accurately identify domain III as the most perturbed region of the protein under these conditions. Additionally, we apply IM-CIU to analyze interleukin dimers, previously linked in therapeutic fusion protein constructs, and demonstrate that they exist in two distinct solution-based conformations. We conclude by outlining the fundamental principles of the IM-CIU method, highlighting its ability to resolve proteins with near-identical collision cross sections, and discussing its potential impact on the development of future pharmaceutical applications.
- 10 June 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (24) , 10003-10012
Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding Rapidly Characterize the Structural Polydispersity and Stability of an Fc-Fusion Protein
Fc-fusion proteins are an emerging class of protein therapeutics that combine the properties of biological ligands with the unique properties of the fragment crystallizable (Fc) domain of an immunoglobulin G (IgG). Due to their diverse higher-order structures (HOSs), Fc-fusion proteins remain challenging characterization targets within biopharmaceutical pipelines. While high-resolution biophysical tools are available for HOS characterization, they frequently demand extended time frames and substantial quantities of purified samples, rendering them impractical for swiftly screening candidate molecules. Herein, we describe the development of ion mobility-mass spectrometry (IM-MS) and collision-induced unfolding (CIU) workflows that aim to fill this technology gap, where we focus on probing the HOS of a model Fc-Interleukin-10 (Fc-IL-10) fusion protein engineered using flexible glycine-serine linkers. We evaluate the ability of these techniques to probe the flexibility of Fc-IL-10 in the absence of bulk solvent relative to other proteins of similar size, as well as localize structural changes of low charge state Fc-IL-10 ions to specific Fc and IL-10 unfolding events during CIU. We subsequently apply these tools to probe the local effects of glycine-serine linkers on the HOS and stability of IL-10 homodimer, which is the biologically active form of IL-10. Our data reveals that Fc-IL-10 produces significantly more structural transitions during CIU and broader IM profiles when compared to a wide range of model proteins, indicative of its exceptional structural dynamism. Furthermore, we use a combination of enzymatic approaches to annotate these intricate CIU data and localize specific transitions to the unfolding of domains within Fc-IL-10. Finally, we detect a strong positive, quadratic relationship between average linker mass and fusion protein stability, suggesting a cooperative influence between glycine-serine linkers and overall fusion protein stability. This is the first reported study on the use of IM-MS and CIU to characterize HOS of Fc-fusion proteins, illustrating the practical applicability of this approach.
- 10 June 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (24) , 10003-10012
Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding Rapidly Characterize the Structural Polydispersity and Stability of an Fc-Fusion Protein
Fc-fusion proteins are an emerging class of protein therapeutics that combine the properties of biological ligands with the unique properties of the fragment crystallizable (Fc) domain of an immunoglobulin G (IgG). Due to their diverse higher-order structures (HOSs), Fc-fusion proteins remain challenging characterization targets within biopharmaceutical pipelines. While high-resolution biophysical tools are available for HOS characterization, they frequently demand extended time frames and substantial quantities of purified samples, rendering them impractical for swiftly screening candidate molecules. Herein, we describe the development of ion mobility-mass spectrometry (IM-MS) and collision-induced unfolding (CIU) workflows that aim to fill this technology gap, where we focus on probing the HOS of a model Fc-Interleukin-10 (Fc-IL-10) fusion protein engineered using flexible glycine-serine linkers. We evaluate the ability of these techniques to probe the flexibility of Fc-IL-10 in the absence of bulk solvent relative to other proteins of similar size, as well as localize structural changes of low charge state Fc-IL-10 ions to specific Fc and IL-10 unfolding events during CIU. We subsequently apply these tools to probe the local effects of glycine-serine linkers on the HOS and stability of IL-10 homodimer, which is the biologically active form of IL-10. Our data reveals that Fc-IL-10 produces significantly more structural transitions during CIU and broader IM profiles when compared to a wide range of model proteins, indicative of its exceptional structural dynamism. Furthermore, we use a combination of enzymatic approaches to annotate these intricate CIU data and localize specific transitions to the unfolding of domains within Fc-IL-10. Finally, we detect a strong positive, quadratic relationship between average linker mass and fusion protein stability, suggesting a cooperative influence between glycine-serine linkers and overall fusion protein stability. This is the first reported study on the use of IM-MS and CIU to characterize HOS of Fc-fusion proteins, illustrating the practical applicability of this approach.
- 16 May 2023
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 34 (6) , 1117-1124
Screening Clones for Monoclonal Antibody Production Using Droplet Microfluidics Interfaced to Electrospray Ionization Mass Spectrometry
As one of the most critical steps in process developmentfor proteintherapeutics, clone selection and cell culture optimization requirea large number of samples to be screened for high titer and desirablemolecular profiles. Typical analytical techniques, such as chromatographicapproaches, often take minutes per sample which are inefficient forlarge-scale screenings. Droplet microfluidics coupled to mass spectrometry(MS) represents an attractive approach due to its low volume requirements,high-throughput capabilities, label-free nature, and ability to handlecomplex mixtures. In this work, we coupled a modified protein cleanupprotocol with a droplet-MS workflow for mAb titer screening to guideclone selection. With this droplet approach we achieved a throughputof 0.04 samples/s with an LoD of 0.15 mg/mL and an LoQ of 0.45 mg/mL.To test its performance in a real-world setting, this workflow wasapplied to a 35-clone screen, where the top 20% producing clones wereidentified. In addition, we coupled our sample cleanup protocol toa high-resolution MS and compared the glycan profiles of the hightiter clones. This work demonstrates that droplet-MS provides a rapidway of clone screening and cell culture optimization based on titerand molecular structure of the expressed proteins. Future work isaimed at increasing the throughput and automation of this droplet-MStechnique.
- 16 May 2023
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 34 (6) , 1117-1124
Screening Clones for Monoclonal Antibody Production Using Droplet Microfluidics Interfaced to Electrospray Ionization Mass Spectrometry
As one of the most critical steps in process developmentfor proteintherapeutics, clone selection and cell culture optimization requirea large number of samples to be screened for high titer and desirablemolecular profiles. Typical analytical techniques, such as chromatographicapproaches, often take minutes per sample which are inefficient forlarge-scale screenings. Droplet microfluidics coupled to mass spectrometry(MS) represents an attractive approach due to its low volume requirements,high-throughput capabilities, label-free nature, and ability to handlecomplex mixtures. In this work, we coupled a modified protein cleanupprotocol with a droplet-MS workflow for mAb titer screening to guideclone selection. With this droplet approach we achieved a throughputof 0.04 samples/s with an LoD of 0.15 mg/mL and an LoQ of 0.45 mg/mL.To test its performance in a real-world setting, this workflow wasapplied to a 35-clone screen, where the top 20% producing clones wereidentified. In addition, we coupled our sample cleanup protocol toa high-resolution MS and compared the glycan profiles of the hightiter clones. This work demonstrates that droplet-MS provides a rapidway of clone screening and cell culture optimization based on titerand molecular structure of the expressed proteins. Future work isaimed at increasing the throughput and automation of this droplet-MStechnique.
- 17 April 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (17) , 6962-6970
Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics
Bispecific antibodies (bsAbs) represent a critically important class of emerging therapeutics capable of targeting two different antigens simultaneously. As such, bsAbs have been developed as effective treatment agents for diseases that remain challenging for conventional monoclonal antibody (mAb) therapeutics to access. Despite these advantages, bsAbs are intricate molecules, requiring both the appropriate engineering and pairing of heavy and light chains derived from separate parent mAbs. Current analytical tools for tracking the bsAb construction process have demonstrated a limited ability to robustly probe the higher-order structure (HOS) of bsAbs. Native ion mobility-mass spectrometry (IM-MS) and collision-induced unfolding (CIU) have proven to be useful tools in probing the HOS of mAb therapeutics. In this report, we describe a series of detailed and quantitative IM-MS and CIU data sets that reveal HOS details associated with a knob-into-hole (KiH) bsAb model system and its corresponding parent mAbs. We find that quantitative analysis of CIU data indicates that global KiH bsAb stability occupies an intermediate space between the stabilities recorded for its parent mAbs. Furthermore, our CIU data identify the hole-containing half of the KiH bsAb construct to be the least stable, thus driving much of the overall stability of the KiH bsAb. An analysis of both intact bsAb and enzymatic fragments allows us to associate the first and second CIU transitions observed for the intact KiH bsAb to the unfolding Fab and Fc domains, respectively. This result is likely general for CIU data collected for low charge state mAb ions and is supported by data acquired for deglycosylated KiH bsAb and mAb constructs, each of which indicates greater destabilization of the second CIU transition observed in our data. When integrated, our CIU analysis allows us to link changes in the first CIU transition primarily to the Fab region of the hole-containing halfmer, while the second CIU transition is likely strongly connected to the Fc region of the knob-containing halfmer. Taken together, our results provide an unprecedented road map for evaluating the domain-level stabilities and HOS of both KiH bsAb and mAb constructs using CIU.
- 17 April 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (17) , 6962-6970
Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics
Bispecific antibodies (bsAbs) represent a critically important class of emerging therapeutics capable of targeting two different antigens simultaneously. As such, bsAbs have been developed as effective treatment agents for diseases that remain challenging for conventional monoclonal antibody (mAb) therapeutics to access. Despite these advantages, bsAbs are intricate molecules, requiring both the appropriate engineering and pairing of heavy and light chains derived from separate parent mAbs. Current analytical tools for tracking the bsAb construction process have demonstrated a limited ability to robustly probe the higher-order structure (HOS) of bsAbs. Native ion mobility-mass spectrometry (IM-MS) and collision-induced unfolding (CIU) have proven to be useful tools in probing the HOS of mAb therapeutics. In this report, we describe a series of detailed and quantitative IM-MS and CIU data sets that reveal HOS details associated with a knob-into-hole (KiH) bsAb model system and its corresponding parent mAbs. We find that quantitative analysis of CIU data indicates that global KiH bsAb stability occupies an intermediate space between the stabilities recorded for its parent mAbs. Furthermore, our CIU data identify the hole-containing half of the KiH bsAb construct to be the least stable, thus driving much of the overall stability of the KiH bsAb. An analysis of both intact bsAb and enzymatic fragments allows us to associate the first and second CIU transitions observed for the intact KiH bsAb to the unfolding Fab and Fc domains, respectively. This result is likely general for CIU data collected for low charge state mAb ions and is supported by data acquired for deglycosylated KiH bsAb and mAb constructs, each of which indicates greater destabilization of the second CIU transition observed in our data. When integrated, our CIU analysis allows us to link changes in the first CIU transition primarily to the Fab region of the hole-containing halfmer, while the second CIU transition is likely strongly connected to the Fc region of the knob-containing halfmer. Taken together, our results provide an unprecedented road map for evaluating the domain-level stabilities and HOS of both KiH bsAb and mAb constructs using CIU.
- 2 July 2020
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 92 (15) , 10327-10335
Enhancing Host-Cell Protein Detection in Protein Therapeutics Using HILIC Enrichment and Proteomic Analysis
Liquid chromatography-mass spectrometry (LC-MS)-based proteomics approaches have been widely used to identify residual host-cell proteins (HCPs) in support of process and product characterization for protein therapeutics. Particularly, these methods can provide a general and unbiased approach for the detection of HCPs and may generate critical information on HCPs that are outside the coverage provided by a conventional immunoassay. A significant technical hurdle for HCP analysis is the overwhelmingly large background of biotherapeutic that obscures HCP detection and quantification. In this work, we developed a method that relies on hydrophilic interaction chromatography (HILIC) for HCP enrichment followed by in situ concentration and digestion prior to LC-MS analysis. This approach has enabled detection of HCPs in drug substance that were not observed in other conventional flow rate LC-MS strategies. For example, 28% of HCPs identified in NISTmAb (20 out of 71) were not previously published or identified by established methods such as the native digestion technique. For an IgG1 protein spiked with 1000 ppm HCP standards, we detected 83 HCPs, 61 out of which were not identified by the native digestion method. Similar improvement in performance was demonstrated for an Fc-fusion protein therapeutic. Our method can be readily implemented in most protein mass spectrometry labs to support process development for protein therapeutics.
- 2 July 2020
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 92 (15) , 10327-10335
Enhancing Host-Cell Protein Detection in Protein Therapeutics Using HILIC Enrichment and Proteomic Analysis
Liquid chromatography-mass spectrometry (LC-MS)-based proteomics approaches have been widely used to identify residual host-cell proteins (HCPs) in support of process and product characterization for protein therapeutics. Particularly, these methods can provide a general and unbiased approach for the detection of HCPs and may generate critical information on HCPs that are outside the coverage provided by a conventional immunoassay. A significant technical hurdle for HCP analysis is the overwhelmingly large background of biotherapeutic that obscures HCP detection and quantification. In this work, we developed a method that relies on hydrophilic interaction chromatography (HILIC) for HCP enrichment followed by in situ concentration and digestion prior to LC-MS analysis. This approach has enabled detection of HCPs in drug substance that were not observed in other conventional flow rate LC-MS strategies. For example, 28% of HCPs identified in NISTmAb (20 out of 71) were not previously published or identified by established methods such as the native digestion technique. For an IgG1 protein spiked with 1000 ppm HCP standards, we detected 83 HCPs, 61 out of which were not identified by the native digestion method. Similar improvement in performance was demonstrated for an Fc-fusion protein therapeutic. Our method can be readily implemented in most protein mass spectrometry labs to support process development for protein therapeutics.
- 1 June 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (6) , 1944-1952
Probing the Tryptophan Environment in Therapeutic Proteins: Implications for Higher Order Structure on Tryptophan Oxidation
- 1 June 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (6) , 1944-1952
Probing the Tryptophan Environment in Therapeutic Proteins: Implications for Higher Order Structure on Tryptophan Oxidation
- 14 November 2017
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 89 (23) , 12749-12755
Codon-Directed Determination of the Biological Causes of Sequence Variants in Therapeutic Proteins
Recombinant monoclonal antibodies (mAbs) manufactured from immortalized mammalian cell lines are becoming increasingly important as therapies. Ensuring the quality of expressed proteins is critical when developing manufacturing processes. Protein sequence variants (PSVs) are a type of product-related variant in which errors in the protein sequence are present. Detecting PSVs and determining their origins, either by DNA mutation or mRNA mistranslation, is critical. Mutations cannot be remediated without developing new clones, which can be costly and time-consuming. In contrast, mistranslation can usually be mitigated by optimizing cell culture conditions. In this work, we first developed a new method to detect low-abundance PSVs with improved sensitivity. Then, a statistical metric was proposed to determine whether the observed PSVs originate from mutation or mistranslation by characterizing the distribution of PSVs. This method was applied to the evaluation of 50 clones from five mAbs programs, allowing for identification of five mutation and 139 mistranslation PSVs. The presence of even a few mutations demonstrates the necessity of clone screening during process development.
- 14 November 2017
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 89 (23) , 12749-12755
Codon-Directed Determination of the Biological Causes of Sequence Variants in Therapeutic Proteins
Recombinant monoclonal antibodies (mAbs) manufactured from immortalized mammalian cell lines are becoming increasingly important as therapies. Ensuring the quality of expressed proteins is critical when developing manufacturing processes. Protein sequence variants (PSVs) are a type of product-related variant in which errors in the protein sequence are present. Detecting PSVs and determining their origins, either by DNA mutation or mRNA mistranslation, is critical. Mutations cannot be remediated without developing new clones, which can be costly and time-consuming. In contrast, mistranslation can usually be mitigated by optimizing cell culture conditions. In this work, we first developed a new method to detect low-abundance PSVs with improved sensitivity. Then, a statistical metric was proposed to determine whether the observed PSVs originate from mutation or mistranslation by characterizing the distribution of PSVs. This method was applied to the evaluation of 50 clones from five mAbs programs, allowing for identification of five mutation and 139 mistranslation PSVs. The presence of even a few mutations demonstrates the necessity of clone screening during process development.
- 1 July 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 141, 32-38
Identification of a host cell protein impurity in therapeutic protein, P1
- 1 July 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 141, 32-38
Identification of a host cell protein impurity in therapeutic protein, P1
- 2 June 2017
- Published by Wiley
- p. 221-249
Characterization of Protein Therapeutics by Mass Spectrometry
- 2 June 2017
- Published by Wiley
- p. 221-249
Characterization of Protein Therapeutics by Mass Spectrometry
- 3 April 2013
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 85 (8) , 3828-3831
Microfabricated Sampling Probes for in Vivo Monitoring of Neurotransmitters
Microfabricated fluidic systems have emerged as a powerful approach for chemical analysis. Relatively unexplored is the use of microfabrication to create sampling probes. We have developed a sampling probe microfabricated in Si by bulk micromachining and lithography. The probe is 70 μm wide by 85 μm thick by 11 mm long and incorporates two buried channels that are 20 μm in diameter. The tip of the probe has two 20 μm holes where fluid is ejected or collected for sampling. Utility of the probe was demonstrated by sampling from the brain of live rats. For sampling, artificial cerebral spinal fluid was infused in through one channel at 50 nL/min while sample was withdrawn at the same flow rate from the other channel. Analysis of resulting fractions collected every 20 min from the striatum of rats by liquid chromatography with mass spectrometry demonstrated reliable detection of 17 neurotransmitters and metabolites. The small probe dimensions suggest it is less perturbing to tissue and can be used to sample smaller brain nuclei than larger sampling devices, such as microdialysis probes. This sampling probe may have other applications such as sampling from cells in culture. The use of microfabrication may also enable incorporation of electrodes for electrochemical or electrophysiological recording and other channels that enable more complex sample preparation on the device.
- 3 April 2013
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 85 (8) , 3828-3831
Microfabricated Sampling Probes for in Vivo Monitoring of Neurotransmitters
Microfabricated fluidic systems have emerged as a powerful approach for chemical analysis. Relatively unexplored is the use of microfabrication to create sampling probes. We have developed a sampling probe microfabricated in Si by bulk micromachining and lithography. The probe is 70 μm wide by 85 μm thick by 11 mm long and incorporates two buried channels that are 20 μm in diameter. The tip of the probe has two 20 μm holes where fluid is ejected or collected for sampling. Utility of the probe was demonstrated by sampling from the brain of live rats. For sampling, artificial cerebral spinal fluid was infused in through one channel at 50 nL/min while sample was withdrawn at the same flow rate from the other channel. Analysis of resulting fractions collected every 20 min from the striatum of rats by liquid chromatography with mass spectrometry demonstrated reliable detection of 17 neurotransmitters and metabolites. The small probe dimensions suggest it is less perturbing to tissue and can be used to sample smaller brain nuclei than larger sampling devices, such as microdialysis probes. This sampling probe may have other applications such as sampling from cells in culture. The use of microfabrication may also enable incorporation of electrodes for electrochemical or electrophysiological recording and other channels that enable more complex sample preparation on the device.